In the largest case-control study so far, Gasior-Perczak et al. found in the Polish population the CHEK2 c.1100delC mutation to be present in 1% of papillary thyroid cancer patients (16/1547), and none in 468 healthy controls (no statistical analysis available). This evidence concerns the gene CHEK2 and thyroid gland papillary carcinoma.